Scorpion Therapeutics picks up $162m Series B

Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing.

7 January 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare Briefs